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In this article, I trace the historic background of clonal deletion and molecular mimicry, two major pillars
underlying our present understanding of autoimmunity and autoimmune disease. Clonal deletion
originated as a critical element of the clonal selection theory of antibody formation in order to explain
tolerance of self. If we did have complete clonal deletion, there would be major voids, the infamous
“black holes”, in our immune repertoire. For comprehensive, protective adaptive immunity, full deletion
is necessarily a rare event. Molecular mimicry, the sharing of epitopes among self and non-self antigens,
is extraordinary common and provides the evidence that complete deletion of self-reactive clones is rare.
If molecular mimicry were not common, protective adaptive immunity could not be all-encompassing.
By taking a fresh look at these two processes together we can envision their evolutionary basis and
understand the need for regulatory devices to prevent molecular mimicry from progressing to
autoimmune disease.
& 2014 Elsevier Ltd.
1. Strategies of immunity
The immune system can be viewed as the evolutionary solution
to the ever present risk of microbial infection (Rose and Mackay,
2014). Humans share with other vertebrates a combination of two
distinct, but interactive, immune systems. The older, constitutive
innate immune system, inherited from our invertebrate predeces-
sors, provides broad, immediate protection against the vast array
of potential infections. It includes protective mechanisms includ-
ing barrier protection afforded by skin and mucous membranes,
and specialized cells and cell products that can contend rapidly
with any microbial invaders that penetrate the barriers.
The second kind of immune response, fashioned in part from
preexisting elements of innate immunity, is the adaptive immune
system found in vertebrates. Rather than the broad, immediate, but
sometimes temporary protection against infection afforded by innate
immunity, the more potent adaptive immunity focuses on key
antigens of a particular pathogen. Adaptive immunity provides the
additional attribute of memory so that immunity once learned is
hastened and ampliﬁed following a second exposure to the same
microorganism. Adaptive immunity depends upon populations of
specialized lymphocytes, T cells and B cells, each of which expresses
a distinct speciﬁc recognition structure or receptor (Delves, 2014).
Unlike the genetically determined innate immune system, the recep-
tors of the lymphocytes are somatically `generated by hypermutation
and random recombination (Jerne, 1971). This stochastic process
provides a sufﬁciently wide repertoire of receptors to enable the
population of lymphocytes to recognize and respond to virtually any
possible intruder entering the body, living or not. Although it takes
days or even weeks for an adaptive immune response to reach
protective levels, its focus on the particular pathogen enables it to
bind with much higher afﬁnity than the broad receptors on cells of the
innate immune system.
To produce their beneﬁcial biologic effects, the lymphocytes
must recognize particular antigenic epitopes on the invader. The
lymphocytes must also receive a non-antigen-speciﬁc stimulatory
signals, signals that are often derived from the earlier, innate
immune response. Because of its potency it is of the greatest
importance that the adaptive immune response be prevented from
attacking antigens of the body of the host where it may do harm in
the form of autoimmune disease.
1.1. Clonal deletion
The success of adaptive immunity rests on the assumption that
the total range of receptors on the lymphocyte population, both T
cells and B cells, is large enough to recognize any potential pathogen.
The antigen selects, binds to and activates the appropriate lympho-
cyte causing it to replicate serially and produce a clone of lympho-
cytes bearing the same antigen-speciﬁc receptor. The clonal selection
theory of Burnet predicted that premature exposure to its cognate
antigen would lead to death of the lymphocyte rather than prolifera-
tion (Burnet, 1959). For example, if an encounter with the cognate
antigen occurs during the generation of the lymphocyte at an early
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time when antigen speciﬁcity is ﬁrst conferred, cell death and
subsequent clonal deletion will result. This process of negative
selection was proposed by Burnet as the mechanism for the
elimination of self-directed lymphocyte clones during development
of the adaptive immune response.
Clonal deletion can occur centrally during the initial differen-
tiation of antigen-speciﬁc T cells or B cells or even later in
peripheral sites. In the case of T cells, the site of T cell differentia-
tion is the thymus (Sprent and Webb, 1995). During the process of
“thymic education”, T cells with their antigen-speciﬁc receptors
encounter corresponding antigen-presenting cells in the thymic
medulla. When the thymic medullary cell presents a particular
epitope of the antigen, responding T cells undergo apoptotic cell
death. In principle, the progency of these cells will, therefore, be
completely absent. The host, unable to respond, will be considered
tolerant of the particular antigen (Hamilton and Crome (Ohashi)).
If one scrutinizes the literature that has accumulated on natu-
rally occurring T cell tolerance in some sixty years since formulation
of the clonal selection theory, one can see that central clonal
deletion represents a spectrum in its effectiveness (Kappler et al.,
1998; MacDonald et al., 1988; Streilein et al., 1982; Wirnsberger
et al., 2011). In a few instances, the elimination process appears to
be complete (Dighiero and Rose, 1999). Examples are best seen in
major cell and tissue antigens, often complexed carbohydrates and
expressed on the cell surface. The major blood group antigens, ABO,
and the Forssman antigen, are prime examples of antigens capable
of inducing complete, speciﬁc clonal deletion. Thus, a blood group A
individual is completely unable to produce anti-A, although a blood
group B individual produces a vigorous response to this closely
related antigen. In examples of complete clonal deletion, it is
usually predictable that the tolerant individual will produce the
antibodies speciﬁc for the absent alloantigen. Thus blood group A
individuals spontaneously produce an anti-B. Similarly, Forssman
negative animals elaborate natural Forssman antibodies.
Prenatal or neonatal exposure to a non-self-antigen can induce a
form of acquired tolerance that can be life-long. In a brief report,
Owen (1945) showed that genetically dissimilar bovine twins
sharing fetal vascular anastomoses will harbor the alloantigenic
red blood cells of the opposite twins. Indeed, Traub's (1936 ) studies
of lymphocytic choriomeningitis virus infections of mice demon-
stated persistance of virus introduced during embryonic or neonatal
life. Such “tolerant” mice may become life-long carriers of the virus
even though they can produce high titers of antiviral antibody and
develop immune complex-mediated glomerenephritis (Oldstone
and Dixon, 1967). In experiments by Jamieson and Ahmed (1987) ,
carrier mice cured of viral infection by adaptive transfer of immune
donor T cells were capable of producing their own population of
cytotoxic T cells. These ﬁndings suggest that acquired immune
tolerance is related mainly to the purging of antigen-speciﬁc T cells
in the thymus and can be reversed by reconstitution with freshly
minted bone marrow-derived T cells. Elimination of virus enabled
the carrier mouse to produce cytotoxic T cells.
At the other end of the clonal deletion spectrum are antigens
that are not well expressed in the thymus. In these instances,
autoimmunity can be induced relatively easily by presenting the
cognate antigen in the proper context. Classical instances are the
tissue antigens from “immunologically privileged” sites such as in
the anterior chamber of the eye, sperm in the testes and, to some
extent, brain (Medawar, 1948). In these organs, allogeneic and even
xenogeneic tissues are able to survive, suggesting some combina-
tion of barriers and local tolerance. When they are presented in
other sites, these “sequestered” antigens readily induce autoim-
mune responses (Streilein et al., 1997). Simply tying the vas
deferens introduces sperm into the body and stimulates sperm-
speciﬁc autoantibodies (Samuel and Rose, 1980). Immune privilege
in the eye can be overcome by increasing the proportion of T cells
bearing a receptor speciﬁc for a retina-speciﬁc antigen (Horai et al.,
2013). A spontaneous form of autoimmune disease may develop in
neonatally thymectomized mice, a process dependent upon the
genetic constitution of the host and the contribution of the host
microbiome (Pillai, 2013). Presumably the production of inﬂamma-
tory immune responses within the lens or other privileged sites
would itself be detrimental to their key functions (Stein-Streilein
and Caspi, 2014) and evolution has provided them with special
mechanisms of tolerance.
The notion that antigen expression in the thymus is key in central
clonal deletion is reinforced by recent studies on immune regulatory
(AIRE) genes (Venanzi et al., 2004; Laan and Peterson, 2013). Muta-
tions or inherited allotypic differences in this gene family determines
the ability of the medullary thymic epithelial cells to acquire and
present a tissue-limited or organ-speciﬁc antigen. The main antigens
that have been associated with AIRE gene mutations are represented
in the endocrine system. Thus, humans with certain alleles in AIRE
gene often suffer from multiple endocrinopathies, a predilection
perhaps related to the pronounced organ-speciﬁc antigens in these
highly specialized organs. Although the presence or dysfunction of
AIRE-like genes in other examples of autoimmune disease is still
unknown, induction of autoimmune disease is t common with tissue-
limited, organ-speciﬁc antigens (Witebsky et al., 1957).
Excluding the polar examples, most antigens entering the body
are likely to be met with some measure of partial clonal deletion
(Gallegos and Bevan, 2006). This gradient may be based primarily on
the afﬁnity between the peptide epitope of the antigen and the T
cells receptor, or on the afﬁnity of the peptide with the major
histocompatibility complex (MHC) element of the presenting cell.
Even subtle alterations of naturally occurring epitopes by chemical
manipulation will sometimes prevent and raise the probability of an
autoimmune disease. Altered cardiac myosin can be used as a vaccine
to prevent or even treat experimental autoimmune myocarditis
(Cihakova et al., 2008). A halogen-derived product raises the anti-
genicity of the liver enzyme CYP2E1 and enhances production of
autoimmune hepatitis in mice (Njoku et al., 2005). Another example
is seen in thyroglobulin where the thyronine epitope with an iodine
substituent is a more active autoantigen than the same peptide
lacking iodine (Barin et al., 2005). There are many other examples
where even minor changes in antigen induced by infection, or by
exposure to drugs or environmental chemicals, may raise the afﬁnity
of antigenic peptides and facilitate an autoimmune disease process
(Nyland et al., 2010).
Clonal deletion of B cells is also incomplete. In addition to
negative selection during their generation in the bone marrow, B
cell can undergo a process of receptor editing whereby lympho-
cytes with autoreactive receptors can avoid deletion by under-
going a secondary receptor re-arrangement (Prak et al., 2011).
Since clonal deletion is generally imperfect, lymphocytes capable
of self-directed autoimmune responses are common (Ada and Rose,
1988; Enouz et al., 2012). All through the lifespan, diverse T and B
cells are being generated in the bone marrow and developing in the
thymus or some peripheral lymphoid organ. In the case of B cells,
their products are commonly encountered in the form of natural
autoantibodies; that is, autoantibodies induced without a deliberate
or deﬁned process of immunization (Rose and Brinckerhoff, 1969).
Much of the total immunoglobulin content of human serum
comprises naturally occurring autoantibodies (Avrameas et al.,
1983). They are present in all normal subjects, although often
somewhat difﬁcult to demonstrate because of their low afﬁnity
and extensive cross-reactivity. Self-reactive T cells are also well
described in the literature, but their low binding afﬁnity presents
special problems. T cell “degeneracy” raises the issue of deﬁning
and maintaining T cell speciﬁcity (Van den Berg et al., 2001).
Although some form of B cell and T cell natural autoimmunity
is universal, autoimmune disease, relatively speaking, is not a
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frequent event. (It must be pointed out, however, that between 5%
and 8% of Americans have some type of autoimmune disease.)
Because of the imperfect nature of clonal deletion, both passive
and active methods of regulation are required (Rose et al., 1980). In
the case of B cells, the encounter with an antigen in the absence of
the required non-antigen-speciﬁc signals may lead to a state of
suspended animation or anergy (Nossal, 1994). This process can be
reversed if the secondary stimulatory signals are later provided
from some source such as an infection. T cell unresponsiveness has
also been well described and related not only to the absence of the
non-antigenic signals, but to the mode of antigen presentation
itself. Thus, administration of antigen by certain routes such as oral
or nasal, or presentation by particular populations of dendritic
cells, can result in negative rather than positive responses
(Guerder et al., 2013).
In addition to passive regulation, active regulation is an impor-
tant mechanism for presenting the everyday autoimmune
responses from reaching a clinically signiﬁcant level (Wirnsberger
et al., 2011). Specialized populations of T lymphocytes, naturally
occurring or induced, and acting by an antigen-speciﬁc or non-
speciﬁc manner are described frequently in the current literature. A
host of other cells including B cells, NK cells and myelocytes, as well
as cell products, contribute actively to maintaining the homeostatic
control of self-reactive lymphocytes (Shen et al., 2014; Lindau et al.,
2012).
As implied above, T cells and B cells are tailored to recognize and
respond to particular short amino acid sequences. The sequences
may be continuous or discontinuous. Neighboring sequences may
exert effects during the immunization process. Yet, the reactive
sequences do not always have to be perfect duplicates of the
peptide used for immunization. A few key anchoring amino acids
at certain sites within the immunogenic peptide sequence are
mainly responsible for establishing T cell receptor afﬁnity for the
peptide. An antigen-speciﬁc T cell is able to recognize a somewhat
broader array of peptides than the one that induced it.
Incomplete clonal deletion has a sound evolutionary basis. It is
important that a host recognize the pathogenetic epitopes of a
near-universe of potential pathogens. There is even chance that an
individual may have long standing memory of some novel patho-
gen due to a prior adaptive immune response if some measure of
cross reaction among epitopes occurs. Protection of the host would
be quicker and more effective, and more readily spread to addi-
tional epitopes, due to molecular mimicry.
2. Molecular (epitope) mimicry
The concept of molecular mimicry was ﬁrst proposed in a
seminal paper by Damian (1964). He suggested that microorgan-
isms may develop antigen determinants that resemble antigens of
the host as a mean of avoiding recognition and elimination by the
host. There are, in fact, several examples where molecular mimicry
appears to be in effect. The beta hemolytic streptococcus will
sometimes have a hyaluronic acid covering. Since hyaluronic acid
is present in human joint ﬂuid, the host may be partially tolerant
of the bacterium.
The concept of molecular mimicry was soon expanded by
Fujinami et al. (1983) and Oldstone (1998) to explain autoimmune
disease. They suggested that because of the common cross reactions
between epitopes of invading microorganisms and antigens present
in the body, the miocroorganism may stimulate an injurious auto-
immune response. Molecular mimicry, or more narrowly deﬁned,
epitope mimicry, may be a common cause of human autoimmune
diseases (Fujinami and Oldstone, 1985; Cusick et al., 2012).
There are now several examples of epitope mimicry in human
disease. The best studied instance is the induction of rheumatic
fever by Streptococcus pyogenes. The epidemiologic association of
the beta hemolytic streptococcus with rheumatic fever arose as a
by-product of the second World War. I have recently described it
in another article (Rose, 2014). Brieﬂy, a train of evidence devel-
oped showing that antibodies from rheumatic fever patients often
reacted with the M antigen of the hemolytic streptococcus.
Conversely, streptococcal pharyngitis often was associated with
production in children of autoantibodies to structures in a heart. In
a series of eligent investigations, Madeleine Cunningham was able
to deﬁne the streptococcal antigens responsible for cellular and
antibody responses in rheumatic heart disease (Cunningham,
2012). She has used these deﬁned antigens to reproduce the
cardinal pathologic signs of rheumatic heart disease rodents. There
are a few other examples where the evidence that epitope
mimicry is a cause of a particular disease has been well supported
by reproducing the disease experimentally (Getts et al., 2013). One
form of Guillain Barre syndrome is associated with Campylobacter
jejuni (Sheikh et al., 2004). Another example may be Lyme disease
where there is mimicry between the outer surface protein A of
Borrelia burgdorferi and the human's leukocyte function-associated
antigen-1 (Gross et al., 1998). There is a body of evidence
suggesting that a childhood form of narcolepsy is associated with
H1N1 inﬂuenza vaccine (Lind et al., 2014).
Given the amount of attention paid to molecular mimicry as a
cause of autoimmune disease in recent years, it is surprising that
there are not more well documented instances in the human (Rose
and Mackay, 2000). In most cases investigators readily demon-
strate autoantibodies induced by a pathogen that cross react with
an antigen of the host. In some studies, it has been possible to
show that antigen-speciﬁc self-reactive T cells are present in the
blood. The problem is that when studied, these antibodies and T
cells react with many other antigens that have no known rele-
vance to the clinical disease (Bachmaier et al., 1999). Sometimes
the antibodies actually react with plant proteins as well as with a
long list of animal peptides (Wucherpfennig and Strominger, 1995;
Massilamany et al., 2013). There are still only a few instances
where the mimicking peptide has been found capable of inducing
a replica of the disease in an experimental animal. Thus, current
evidence establishes that molecular mimicry is a common event,
following many infections, but not necessarily a common initiating
cause of human autoimmune disease (Fujinami et al., 2006).
3. Evolutionary imperatives
Evolutionary selection requires that a human host be able to
respond to the great majority of present and future pathogens as
rapidly and effectively as possible. At the same time, autoimmune
responses that lead to injury of the host must be avoided. Evolution
dictates that these two imperatives be balanced. We know that
many of the epitopes of the pathogen, including the critical ones
that afford protection to the host, may be mimicked in the body of
the host. If clonal deletion were thorough and complete, the host
would be unable to respond to many critical antigens because they
are represented in the host's body. The result would be a “black
hole”, a void in the immunologic repertoire that compromises
effective protection against the invading microorganisms. Clearly,
it is imperative that clonal deletion be incomplete and autoimmu-
nity is generated to a large array of self-antigens throughout the life
span (Ada and Rose, 1988). This continuing risk must be carefully
regulated on a daily basis. Should regulation fail either generally or
in reference to a particular pathogeneic (protective) epitope, auto-
immune disease may ensue.
The probability of autoimmune disease rises with the strength
of the stimulus and the genetics of the host. While heredity in a
heterogeneous population like humans is only a minor factor in
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determining the risk of developing an autoimmune disorder
(usually there is less than 50% concurrence even in identical
twins), inbreeding of animals has made it a determining factor,
not only in rats and mice, but sometimes in guinea pigs and beagle
dogs. Our initial discovery that the major histocompatibility
complex is the source of the main susceptibility genes in thyr-
oiditis has been established in virtually all autoimmune diseases in
animals and humans (Vladutiu and Rose, 1971; Bacon et al., 1974;
Vladutiu and Rose, 1974). The remaining inherited susceptibility is
apportioned among a large number of genes, most of which
contribute a small measure of susceptibility (Beisel et al., 1982).
Many of these genetic alleles are normally involved in regulation
of the immune response, in lymphocyte migration, or in target
antigen susceptibility. Deﬁning the genetic predisposition to
autoimmunity, both general and disease-speciﬁc, has been a major
advance in both basic and applied immunology.
Another component of genetic susceptibility to autoimmune
disease is sex since the great majority of autoimmune disease
patients are female. It must be recognized, however, that the
differences in sex preference among different diseases represents a
spectrum of susceptibilities from diseases like Graves' disease and
lupus, which are highly biased towards females to rheumatoid
arthritis and multiple sclerosis that are more balanced in sex
predilection to few diseases including myocarditis which occurs
more in males. Such a spectrum underlines the complexity of sex
and the endocrine network in inﬂuencing the autoimmune response.
The intrinsic potency of an autoantigenic molecule is still
unclear, but the importance of context in determining the strength
of an autoimmune stimulus can be termed the “adjuvant” effect.
We were ﬁrst impressed by the importance of adjuvant in
determining whether an autoimmune response resulted in benign
autoantibody production or pathogenic autoimmunity in our ﬁrst
publications on experimental autoimmune thyroiditis (Rose and
Witebsky, 1958). When the mouse model became available, we
showed that the details of preparing and applying Freund adjuvant
are critical in inducing autoimmune disease (Rose et al., 1971).
Time has shown that the number of adjuvants affective in inducing
autoimmune disease is rather limited, representing mainly the
presence of mycobacterium in Freund adjuvant and bacterial
lipopolysaccharide (Esquivel et al., 1977). Both of these microbial
products act on the innate immune system, illustrating the pivotal
role of the initial immune response in determining the signals that
lead to adaptive immunity. Yet, it must be remembered that
autoimmune disease can be induced even in the absence of an
artiﬁcial adjuvant if a foreign antigen is used in immunization
(Witebsky et al., 1957). Administering early inﬂammatory cyto-
kines like IL1β and TNFα can induce autoimmune diseases even in
mice that are genetically determined poor responders in experi-
mental immunization (Lane et al., 1991, 1992).
The progression of adaptive immunity depends upon altering
the delicate balance between vectors that promote disease and
countervailing effectors that suppress the pathogenic process. This
homeostatic balance is well illustrated through the classic inves-
tigations of Nishizuka et al. (1973) on neonatally thymectomized
mice and Penhale et al. 1973) on thymectomized, irradiated rats.
Our own studies of the OS chicken, which is genetically selected
for spontaneous production of autoimmune thyroiditis, showed
that thymectomy of the birds at an early post-hatching age
signiﬁcantly increased the severity of thyroid disease (Welch et
al., 1973). Similar ﬁndings were obtained in the BUF rat which also
developed spontaneous thyroidits (Silverman and Rose, 1974). The
affect of thymectomy is closely age-related since thymectomy
reduces autoimmune thyroid diseases only at early stages of
development (Rose 1975, 2008). A distinict population of T cells
capable of downregulating an autoimmune response is generated
in the thymus and later migrates to peripheral sites (Rose and
Talor, 1991). These studies foreshadowed the existence of a
population of thymus-derived natural regulators and lead to the
current delineation of CD4þ/CD25/FoxP3 regulatory T cells
(Sakaguchi and Rose, 1988). TP cell populations can serve as
immune regulators. Under various conditions, the prior literature
on CD8þ suppressor cells is still valid even if the population was
never clearly separated from CD8þ effector T cells. The role of
regulatory B cells are now well established (Mauri and Blair, 2014;
Lin et al., 2014). Myeloid-derived suppressor cells, prominent in
tumor immunology, are likely equally effective in some circum-
stances in autoimmune disease (Li et al., 2014).
As regulatory cell populations were being recognized, cell
products with regulatory functions also become evident. Some
clinical experiments arise because of the application of these
regulators in cancer immunology. For example, patients given
antibodies to CTLA4 are prone to a rare autoimmune endocrino-
pathy hypothysitis (Iwama et al., 2014). Current studies using anti-
PD1 or anti-PDL1 already have suggested some risk of heightened
autoimmunity (Kong & Flynn, 2014). This represents an area of
research demanding greater attention for both the fundamental
lessons it can teach us and the practical knowledge it can impart
for clinical application.
Recent years has seen a recurrence of interest in the microbial
population that inhabits the surfaces of the human body, including
the intestines, mouth and skin (Belkaid and Hand, 2014). Now that
the microbiome project has given science the tool of genetic
identiﬁcation of these commensal bacterial, associations with
particular DNA patterns are even particular microorganisms with
autoimmune disease has become evident. This ﬁnding would
certainly be gratifying to Metchnkoff who ﬁrst put us on the track
of the innate immune system and predicted that the diet would be
an important inﬂuence on the immune response.
Evolution demands that immunologic homeostasis be carried
out on two levels. At the macro level the adaptive immune system
is genetically constructed of counterveiling vectors such as reg-
ulatory cells and their cytokine products. They are constantly on
guard to prevent the progression of benign naturally occurring
autoimmunity as it arises daily to life-threatening autoimmune
disease. On the micro level, homeostasis resets all through the life
span because of the changing internal and external environment.
External agents such as microorganisms or chemicals require
shifts to the homeostatic balance as do the changes in hormones
that require constant resetting. Being able to reset homeostasis
continuously is the requisite of immunologic good health.
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